Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Classical hematology 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Congenital Abnormalities 2Breast Neoplasms 2Blast Crisis 2Uterine Cervical Neoplasms 1Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Tretinoin 2Gemcitabine 2venetoclax 1trametinib 1talazoparib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1isoquercitrin 1idelalisib 1ferric carboxymaltose 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1darolutamide 1dacomitinib 1dabrafenib 1copanlisib 1cobimetinib 1cabozantinib 1cabazitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Tretinoin × Classical hematology × Clear all
NCT07586813 2026-05-14

N01-A-PICIT-GI

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡